Pfizer/Lilly ready to ditch painful past with new tanezumab trials
This article was originally published in Scrip
Executive Summary
After five years of waiting, Pfizer and Lilly are ready to restart late-stage clinical trials for the pain drug tanezumab, the big pharmas announced 23 March. The move forward scores Pfizer a $200m milestone payment and signals a jumpstart for the class of drugs.